• Site map
  • Contacts
  • Links
  • Home Page
  • EMVDA
  • EURHAVAC
  • Malaria - The Disease
  • Press Releases
  • EMVI Statutes
  • Board Members and Scientific Advisory Committee Members
  • Memoranda of Understanding and Intent
  • EMVI Strategy
  • Project Portfolio
    • Polyprotein FP9 PP and MVA PP Phase Ia Oxford
    • PfAMA1 Phase Ia Nijmegen
    • PfAMA1 - DDB-TDA
    • PfAMA1 - Second Generation
    • PfAMA1 - Phase Ib Mali
    • GMZ1 (PfGLURP) in the L lactis system
    • GMZ2 Phase Ia Tübingen
    • GMZ2 - DDA-TDB
    • GMZ2 Phase Ib in adults Gabon (AMANET)
    • GMZ2 Phase Ib in African children Gabon (AMANET)
    • JAIVAC-1 Phase I in adults
    • Var2-CSA DBL3-X and Var2CSA
    • TBV - Pf48-45
    • Completed Trials
  • Annual Reports
  • The Donors
  • Mid-Term Review 2005
  • Directives - Guidelines - Regulations
  • Meeting Reports
  • Procedures
  • Calls
  • Vacancies

Print page

GMZ1 (PfGLURP) in the L. lactis system

The further clinical development of GLURP as LSP has ceased. Based on results of the Phase Ia clinical trial of GLURP as LSP, it was decided to pursue GLURP as a recombinant L. lactis protein called GMZ1. At the SAC Portfolio Review Meeting in Copenhagen in October 2006, SAC recommended that the development of GMZ1 be put on hold while the results of the GMZ2 safety and preliminary immunogenicity are generated, and that no further funding should be made available for GMP lots of GMZ1 at present.